Ascensia leads $36M round for glucose sensor startup Sava

Ascensia has led a $36 million funding round for Sava, a startup developing a wearable device to continuously monitor glucose and other biomarkers. The companies also entered an exclusive sales agreement, MedTech Dive reported.

Sava’s sensor targets a market long dominated by glucose-only monitors. While MedTech Dive did not specify which additional biomarkers the device tracks, the move aligns with broader industry shifts toward multi-analyte wearables, particularly in chronic disease management. The investor behind this deal has historically focused on this therapeutic area, suggesting the partnership may prioritize scaling Sava’s technology within existing distribution channels.

The funding round stands out amid a quiet period for European startups, as noted in StartupReader’s weekly roundup for the week ending September 4. While AI startups continue to attract outsized investment—Discovery Loop’s $50 billion valuation target being the latest example—healthtech deals have remained relatively steady but less flashy. The $36 million figure, while not among the largest rounds of the year, reflects sustained interest in medtech innovation outside of AI and fintech.

What remains unclear is how Sava’s product will differentiate itself from established players in the space, or whether the exclusive sales deal will limit its reach. The next milestone to watch will be regulatory approvals and commercial launch timelines, which could clarify whether the wearable is positioned as a niche tool for complex patients or a broader competitor in the chronic disease management market.

Sources: medtechdive.com